Iterum Therapeutics PLC
ITRM
View Detailed Chart
0.077USD
-0.099-56.31%
Market hours （ET）Quotes delayed by 15 min
67.38KMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-56.31%
5 Days
-52.32%
1 Month
-70.93%
6 Months
-88.77%
Year to Date
-77.04%
1 Year
-93.90%
View Detailed Chart
TradingKey Stock Score of Iterum Therapeutics PLC
Currency: USD Updated: 2026-03-27Key Insights
Iterum Therapeutics PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 161 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Iterum Therapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Iterum Therapeutics PLC Highlights
StrengthsRisks
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Overvalued
The company’s latest PE is -0.05, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.86M shares, decreasing 56.94% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 0.00 shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
9.000
Target Price
+5013.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Iterum Therapeutics PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Iterum Therapeutics PLC Info
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Ticker SymbolITRM
CompanyIterum Therapeutics PLC
CEOFishman (Corey N)
Websitehttps://www.iterumtx.com/
Related Instruments
-1.06%
-0.45%
+1.19%
+5.86%
-0.77%
+0.84%
+0.54%
-0.92%
-0.59%
+2.14%
-3.02%
+0.40%
+0.58%
+2.39%
+1.89%
0.00%
-0.45%
-0.88%
-0.68%
+1.05%Popular Symbols
246.710
-2.090 (-0.84%)
165.335
-2.185 (-1.30%)
66349.720
-234.330 (-0.35%)
251.150
-24.190 (-8.79%)
2016.260
+16.260 (+0.81%)
355.100
-6.730 (-1.86%)
4496.740
+4.220 (+0.09%)
103.382
+2.773 (+2.76%)
1.146
-0.005 (-0.44%)
159.672
-0.580 (-0.36%)
